41
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2009
Vinflunine
Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
Consultants in Medical Oncology and Hematology, Drexel Hill
Peninsula Cancer Institute, Newport News
Northeast Georgia Medical Center, Gainesville
Integrated Community Oncology Network, Jacksonville
Florida Hospital Cancer Institute, Orlando
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Associates in Hematology Oncology, Chattanooga
Chattanooga Oncology Hematology Associates, Chattanooga
Consultants in Blood Disorders and Cancer, Louisville
Oncology Hematology Care, Cincinnati
South Texas Oncology and Hematology, San Antonio
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
SCRI Development Innovations, LLC
OTHER